$21.51
1.06%
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US52490G1022
Symbol
LEGN

Legend Biotech Corp - ADR Stock price

$21.51
-5.18 19.41% 1M
-14.40 40.10% 6M
-0.23 1.06% YTD
-13.22 38.07% 1Y
-28.41 56.91% 3Y
-6.48 23.15% 5Y
-15.49 41.86% 10Y
-15.49 41.86% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.23 1.06%
ISIN
US52490G1022
Symbol
LEGN
Industry

New AI Insights on Legend Biotech Corp - ADR Insights AI Insights on Legend Biotech Corp - ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$4.0b
Enterprise Value
$3.4b
Net debt
positive
Cash
$992.7m
Shares outstanding
369.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.4 | 3.8
EV/Sales
3.8 | 3.2
EV/FCF
negative
P/B
4.0
Financial Health
Equity Ratio
62.3%
Return on Equity
-17.0%
ROCE
-14.9%
ROIC
-47.0%
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$909.0m | $1.1b
EBITDA
$-167.6m | $-143.9m
EBIT
$-190.6m | $-158.0m
Net Income
$-240.0m | $-355.4m
Free Cash Flow
$-188.2m
Growth (TTM | estimate)
Revenue
74.7% | 68.5%
EBITDA
49.0% | 48.9%
EBIT
45.7% | 48.2%
Net Income
31.0% | -100.7%
Free Cash Flow
-6.7%
Margin (TTM | estimate)
Gross
60.6%
EBITDA
-18.4% | -13.6%
EBIT
-21.0%
Net
-26.4% | -33.6%
Free Cash Flow
-20.7%
More
EPS
$-0.7
FCF per Share
$-0.5
Short interest
14.9%
Employees
3k
Rev per Employee
$240.0k
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Legend Biotech Corp - ADR forecast:

22x Buy
92%
2x Hold
8%

Analyst Opinions

24 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
92%
Hold
8%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
909 909
75% 75%
100%
- Direct Costs 359 359
87% 87%
39%
550 550
68% 68%
61%
- Selling and Administrative Expenses 323 323
23% 23%
36%
- Research and Development Expense 418 418
1% 1%
46%
-168 -168
49% 49%
-18%
- Depreciation and Amortization 23 23
5% 5%
3%
EBIT (Operating Income) EBIT -191 -191
46% 46%
-21%
Net Profit -240 -240
31% 31%
-26%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Positive
Barrons
25 days ago
Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm's once-daily pill.
Neutral
GlobeNewsWire
28 days ago
SOMERSET, N.J., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced new long-term clinical and translational data for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) from the CARTITUDE-1 and CARTITUDE-4 studies in relapsed / refractory multiple myeloma (RRMM) patients. In triple-class-exposed patients wh...
Positive
Seeking Alpha
about one month ago
Following Legend Biotech's solid financial results for Q3, its average PT rose to $74.90, which implies an upside of about 171.2% from its current stock price. Thanks to increased demand for its "gem" called Carvykti, adjusted net loss decreased by 55.2% to $18.8 million in Q3. A key reason for its growing sales is its superior efficacy compared to Elrexfio, Abecma, and Tecvayli.
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 2,600
Founded 2014
Website investors.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today